<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<title>NCT04739800 – A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab</title>
<link rel="stylesheet" href="../assets/styles.css"/>
</head><body><div class="container">
  <a href="../index.html">← Back to index</a>
  <h1>NCT04739800</h1>

  <div class="card">
    <div><strong>Title:</strong> A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab</div>
    <div class="meta"><strong>Year:</strong>  &nbsp; <strong>Authors:</strong> —</div>
    <div class="meta"><a href="https://clinicaltrials.gov/study/NCT04739800" target="_blank" rel="noopener">Registry page</a></div>
  </div>

  <div class="card">
    <h3>Documents (from CSV)</h3>
    <ul class="list">
      <li>📄 <a href="https://cdn.clinicaltrials.gov/large-docs/00/NCT04739800/Prot_SAP_000.pdf" target="_blank" rel="noopener">Study Protocol and Statistical Analysis Plan</a></li>
<li>📄 <a href="https://cdn.clinicaltrials.gov/large-docs/00/NCT04739800/ICF_001.pdf" target="_blank" rel="noopener">Informed Consent Form</a></li>
    </ul>
  </div>

  <div class="card">
    <h3>Preview</h3>
    <iframe class="pdf-iframe" src="https://mozilla.github.io/pdf.js/web/viewer.html?file=https://cdn.clinicaltrials.gov/large-docs/00/NCT04739800/Prot_SAP_000.pdf"></iframe>
  </div>
</div></body></html>
